Canutillo Independent School District

Board Presentation September 23rd, 2025



©2025 ARTHUR J. GALLAGHER & CO.



Financial Summary


Year over Year Plan Comparison

	Jan 2024 – Dec 2024	Jan 2025 – July 2025
Average Subscribers	711	506
Average Membership	1,123	808
PEPM Claims + Fixed Cost	\$1,019.35	\$884.86
Medical Paid Claims	\$6,102,262	\$1,997,593
Pharmacy Paid Claims	\$2,638,240	\$1,042,925
BCBSTX Runout Claims	-	\$165,845
Access Fees	\$8,739	-
Claim Wire Fees		\$14,104
Stop Loss Reimbursement	(\$1,878,561)	(\$88,077)
Total Net Claim Payments	\$6,870,680	\$3,132,390
Total Plan Cost (Net claim + fixed costs)	\$8,700,113	\$3,750,262
Employer Cost (after Employee Contributions)	\$7,282,184	\$2,794,920




Enrollment Per Plan
Based on data from the following time-period: Jan 2024 – July 2025

There was a large shift in subscriber count between the two plans beginning in 2025. Most of the population is now concentrated in the CDHP plan, whereas the Basic plan was more popular in 2024.





Current Plan Year Claims Comparison



Traditional Summer Claims Spike

Claims include BCBS runout.

Large Claimants Comparison

There were 24 large claimants (over \$62,500) in 2024.

These claims totaled \$4,489,404, which was 51.3% of gross claims for the plan year.

14 claimants hit the specific deductible of \$125,000 in 2024 and stop loss reimbursed \$1,878,561.

So far in 2025, Gallagher is tracking nine large claimants who have accrued \$1,236,402 since January.



2025 High-Cost Claimants over \$50K

Plan	2	25-Jan	2	25-Feb	25-Mar	25-Apr	;	25-May	25-Jun	25-Jul	T	otal Paid	Diagnosis
CDHP	\$	-	\$	-	\$ 83,380	\$ 32,636	\$	187,427	\$ 18,153	\$ 25,288	\$	346,884	Myelodysplastic Syndromes
CDHP	\$	-	\$	61,153	\$ 17,965	\$ 38,886	\$	68,824	\$ 31,653	\$ 577	\$	219,058	Malignant Neoplasm of Brain
CDHP	\$	-	\$	-	\$ 84,376	\$ 22,208	\$	6,859	\$ 7,027	\$ 31,835	\$	152,305	Malignant Neoplasm of Breast
CDHP	\$	-	\$	-	\$ -	\$ -	\$	-	\$ 86,172	\$ 59,941	\$	146,113	Cardiovascular
CDHP	\$	-	\$	-	\$ -	\$ -	\$	53,826	\$ 20,677	\$ 20,531	\$	95,034	Depression
CDHP	\$	-	\$	-	\$ -	\$ -	\$	-	\$ 88,545	\$ 248	\$	88,793	Retropharyngeal Abscess
Basic	\$	-	\$	-	\$ -	\$ -	\$	-	\$ -	\$ 71,989	\$	71,989	Cytomegaloviral Diseases
CDHP	\$	-	\$	-	\$ -	\$ -	\$	-	\$ -	\$ 62,538	\$	62,538	Gynecological A
CDHP	\$	-	\$	-	\$ -	\$ -	\$	-	\$ -	\$ 53,360	\$	53,360	Polyp of Sinus
Total \$	\$		\$	61,153	\$ 185,721	\$ 93,730	\$	316,936	\$ 252,227	\$ 326,307	\$	1,236,074	
Total Claimants	5	0		1	3	3		4	6	9		9	

Financial Reporting – Pharmacy

2025 Plan Year

Top Drugs by Spend										
YTD Rank	Brand Name	Therapeutic Class	Claimants	Scripts	Amount Paid					
1	Ozempic	Diabetes	21	82	\$99,944					
2	Mounjaro	Diabetes	14	49	\$63,190					
3	Dupixent	Eczema Agent	4	13	\$46,622					
4	Syrizi Pen	Inflammatory Disorders	1	2	\$39,728					
5	Rinvoq	Immunity Disorders	2	8	\$38,891					
6	Vraylar	Antipsychotic	5	24	\$37,492					
7	Enbrel Sureclick	Autoimmune	1	3	\$33,957					
8	Bimzelx	Psoriasis	1	5	\$32,330					
9	Prevymis	Antiviral	1	4	\$29,503					
10	Jardiance	Diabetes	7	19	\$23,913					

Top Drugs Total Paid = \$445,570 and accounts for 42.7% of Total Paid Rx.



Financial Summary

Rates - 2026

			Current			Renewal		Change	
Coverage Tier	Avg Enrollment	Employee	District	Total Rates	Employee	District	Total Rates	Employee	District
Basic									
Employee Only	123	\$228.64	\$623.00	\$851.64	\$228.64	\$723.00	\$951.64	0%	16.1%
Employee + Spouse	5	\$651.52	\$623.00	\$1,274.52	\$651.52	\$723.00	\$1,374.52	0%	16.1%
Employee + Child(ren)	15	\$498.39	\$623.00	\$1,121.39	\$498.39	\$723.00	\$1,221.39	0%	16.1%
Employee + Family	4	\$921.27	\$623.00	\$1,544.27	\$921.27	\$723.00	\$1,644.27	0%	16.1%
CDHP									
Employee Only	231	\$110.85	\$623.00	\$733.85	\$110.85	\$723.00	\$833.85	0%	16.1%
Employee + Spouse	15	\$591.45	\$623.00	\$1,214.45	\$591.45	\$723.00	\$1,314.45	0%	16.1%
Employee + Child(ren)	92	\$539.49	\$623.00	\$1,162.49	\$539.49	\$723.00	\$1,262.49	0%	16.1%
Employee + Family	22	\$862.37	\$623.00	\$1,485.37	\$862.37	\$723.00	\$1,585.37	0%	16.1%
Plan Cost Composite	507	\$269.08	\$623.00	\$892.08	\$269.08	\$723.00	\$992.08		
PCORI Fees Annual		\$0.00 \$1,637,095	\$0.50 \$3,793,358	\$0.50 \$5,430,453	\$0.00 \$1,637,095	\$0.54 \$4,402,018	\$0.54 \$6,039,113		
Change From Current (\$) Change From Current (%)					\$0.00 0%	\$608,660 16%	\$608,660 16%		

Thank you!

